Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC).
It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor
associated antigens, potentially increasing the response to immune therapy not just locally,
but systemically. In addition, there is now positive data with immune therapy in advanced
HCC, there is renewed interest in the combination of local therapy and systemic therapy in
Barcelona Clinic Liver Clinic B (BCLC B) patients with systemic therapies other than
sorafenib. Based on this data, the investigators plan to examine the atezolizumab and
bevacizumab combination with Transarterial Chemoembolization (TACE) in patients with BCLC B
HCC.